Insitro
SF 8.2ML drug discovery with proprietary biology data
ML drug discovery with proprietary biology data
AI-powered small molecule design
Quick decision guide
Not enough differentiated product data yet to make a strong automatic pick.
Overview
Insitro is a machine learning drug discovery company that combines proprietary biological data generation with predictive modeling for drug targets. The product is positioned around R&D acceleration and computational biology rather than guaranteed clinical outcomes, and engagement typically happens through pharma partnerships rather than self-serve subscription buying. Buyers should weigh data access requirements, expected timelines to validated leads, and the cost structure across collaborations before committing to a long discovery program today.
For pharma partners on data-rich discovery programs, Insitro is worth a serious look thanks to full-stack ml plus wet-lab integration. The honest trade-off is that engages mainly via partnership not subscription. Pricing is sales-led and scoped per buyer rather than posted publicly. Buyers should still verify EHR or workflow fit, scope, and support before committing.
Atomwise is an AI-powered drug discovery platform that helps pharmaceutical and biotechnology organisations identify potential small-molecule medicines using deep learning. Built for research teams rather than individual users, it combines virtual screening, structure-based modelling and biological data analysis to support early-stage drug discovery.
• Built for pharmaceutical and biotechnology organisations seeking to accelerate small-molecule drug discovery with AI.
• Uses AtomNet deep learning technology to identify potential drug targets, screen compounds and support structure-based drug design.
• Supports drug discovery across multiple therapeutic areas through research partnerships with pharmaceutical companies.
• Available through partnership agreements rather than self-service, with custom pricing and implementation tailored to each organisation.
Atomwise is best suited to pharmaceutical and biotechnology organisations investing in AI-assisted drug discovery, although its partnership-based model may be less suitable for smaller research teams looking for self-service software.
Side-by-side
OVERLAP
Both tools cover similar catalog signals. The deciding factor is usually workflow fit, implementation needs, and ecosystem fit.
Shared capabilities
Shared workflows
Feature check
The trade-offs
Final verdict
Current catalog data shows meaningful overlap between Insitro and Atomwise. Use the signals below to decide based on workflow, ecosystem, pricing, and implementation fit.
Insitro and Atomwise share 9 catalog signals, so the decision should focus on fit rather than broad capability alone.
Insitro has 3 visible decision signals and Atomwise has 3.
Insitro has the higher SoftFinders Score in the current catalog data.